MGMT and central nervous system cancer: With the development of genetics and molecular biology, many molecular biomarkers have been developed for gliomas, such as IDH mutation, ATRX mutation, MGMT methylation status, and 1p/19q status, but they have limitations (Ludwig and Kornblum, 2017).